Posted by Michael Wonder on 19 Apr 2022
Lenvatinib and pembrolizumab in endometrial cancer: patients live significantly longer
19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to other treatment options, an added benefit is not proven.
The combination of lenvatinib and pembrolizumab is approved for the treatment of women with advanced or recurrent endometrial cancer if the disease (at any stage of the disease) has progressed during or after previous platinum-based therapy and curative surgical treatment or radiation is not an option.
In two early benefit assessments, the IQWiG has examined whether the combination has a positive effect on such patients additional benefit compared to the appropriate comparator therapy.
